<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<REGINFO_RIN_DATA xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" RUN_DATE="2026-04-28-04:00" xsi:noNamespaceSchemaLocation="https://www.reginfo.gov/public/xml/REGINFO_XML_Ver10262011.xsd">
    <RIN_INFO>
        <RIN>1117-AB17</RIN>
        <PUBLICATION>
            <PUBLICATION_ID>200904</PUBLICATION_ID>
            <PUBLICATION_TITLE>Unified Agenda of Federal Regulatory and Deregulatory Actions</PUBLICATION_TITLE>
        </PUBLICATION>
        <AGENCY>
            <CODE>1117</CODE>
            <NAME>Drug Enforcement Administration</NAME>
            <ACRONYM>DEA</ACRONYM>
        </AGENCY>
        <PARENT_AGENCY>
            <CODE>1100</CODE>
            <NAME>Department of Justice</NAME>
            <ACRONYM>DOJ</ACRONYM>
        </PARENT_AGENCY>
        <RULE_TITLE>Classification of Three Steroids as Schedule III Anabolic Steroids Under the Controlled Substances Act</RULE_TITLE>
        <ABSTRACT><![CDATA[This rule classifies the following three steroids as anabolic steroids under the Controlled Substances Act (CSA):  Boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione.  The Drug Enforcement Administration (DEA) believes that this action is necessary in order to prevent the abuse and trafficking of these steroids.]]></ABSTRACT>
        <PRIORITY_CATEGORY>Other Significant</PRIORITY_CATEGORY>
        <RIN_STATUS>Previously Published in The Unified Agenda</RIN_STATUS>
        <RULE_STAGE>Final Rule Stage</RULE_STAGE>
        <MAJOR>No</MAJOR>
        <UNFUNDED_MANDATE_LIST>
            <UNFUNDED_MANDATE>No</UNFUNDED_MANDATE>
        </UNFUNDED_MANDATE_LIST>
        <CFR_LIST>
            <CFR>21 CFR 1300</CFR>
        </CFR_LIST>
        <LEGAL_AUTHORITY_LIST>
            <LEGAL_AUTHORITY>21 USC 802</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 USC 871 (b)</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 USC 951</LEGAL_AUTHORITY>
            <LEGAL_AUTHORITY>21 USC 958(f)</LEGAL_AUTHORITY>
        </LEGAL_AUTHORITY_LIST>
        <LEGAL_DLINE_LIST/>
        <RPLAN_ENTRY>No</RPLAN_ENTRY>
        <TIMETABLE_LIST>
            <TIMETABLE>
                <TTBL_ACTION>NPRM</TTBL_ACTION>
                <TTBL_DATE>04/25/2008</TTBL_DATE>
                <FR_CITATION>73 FR 22294</FR_CITATION>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>NPRM Comment Period End</TTBL_ACTION>
                <TTBL_DATE>06/24/2008</TTBL_DATE>
            </TIMETABLE>
            <TIMETABLE>
                <TTBL_ACTION>Final Action</TTBL_ACTION>
                <TTBL_DATE>11/00/2009</TTBL_DATE>
            </TIMETABLE>
        </TIMETABLE_LIST>
        <ADDITIONAL_INFO>Docket Number DEA-285</ADDITIONAL_INFO>
        <RFA_REQUIRED>No</RFA_REQUIRED>
        <SMALL_ENTITY_LIST>
            <SMALL_ENTITY>No</SMALL_ENTITY>
        </SMALL_ENTITY_LIST>
        <GOVT_LEVEL_LIST>
            <GOVT_LEVEL>None</GOVT_LEVEL>
        </GOVT_LEVEL_LIST>
        <FEDERALISM>No</FEDERALISM>
        <PRINT_PAPER>No</PRINT_PAPER>
        <INTERNATIONAL_INTEREST>No</INTERNATIONAL_INTEREST>
        <AGENCY_CONTACT_LIST>
            <CONTACT>
                <FIRST_NAME>Christine</FIRST_NAME>
                <LAST_NAME>Sannerud</LAST_NAME>
                <MIDDLE_NAME>A.</MIDDLE_NAME>
                <SUFFIX>Ph.D.</SUFFIX>
                <TITLE>Chief, Drug and Chemical Evaluation Section, Office of Diversion Control</TITLE>
                <AGENCY>
                    <CODE>1117</CODE>
                    <NAME>Drug Enforcement Administration</NAME>
                    <ACRONYM>DEA</ACRONYM>
                </AGENCY>
                <PHONE>202 307-7183</PHONE>
                <MAILING_ADDRESS>
                    <STREET_ADDRESS>8701 Morrissette Drive,</STREET_ADDRESS>
                    <CITY>Washington</CITY>
                    <STATE>DC</STATE>
                    <ZIP>20537</ZIP>
                </MAILING_ADDRESS>
            </CONTACT>
        </AGENCY_CONTACT_LIST>
    </RIN_INFO>
</REGINFO_RIN_DATA>
